PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.

Slides:

Advertisements

Similar presentations

Corpus Callosum Damage Predicts Disability Progression and Cognitive Dysfunction in Primary-Progressive MS After Five Years.

Advertisements

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.

ADNI PiB Amyloid Imaging Chet Mathis University of Pittsburgh.

Agenda: - Update on master tracers’ segmentation check - Update validation vs pathology - PMT application submission of “Study on the validation of VSRAD”

National Alliance for Medical Image Computing Core DBP Dartmouth Data NA-MIC National Alliance for Medical Image Computing

FOCUS ON NLM RESOURCES: CLINICALTRIALS.GOV. WHAT IS A CLINICAL STUDY?  Research study using human subjects.  Volunteers may have a certain disease or.

Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

ADNI 3 Clinical Core Plans

Public Health Julie C. Chapman, PsyD Director of Neuroscience War Related Illness & Injury Study Center Veterans Affairs Medical Center, Washington, DC.

Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.

MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.

Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI.

MNTP Trainee: Georgina Vinyes Junque, Chi Hun Kim Prof. James T. Becker Cyrus Raji, Leonid Teverovskiy, and Robert Tamburo.

All Hands Meeting 2005 Morphometry BIRN - Overview - Scientific Achievements.

EPAD update José Luis Molinuevo Worldwide-ADNI Update Meeting Friday, July 17, 2015 Washington, D.C.

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.

Alzheimer’s disease Platforms for translational research.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

All Hands Meeting 2004 Title: Planned GCRC-BIRN Collaboration at BWH Jonathan Sacks, PhD.

The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

All Hands Meeting 2005 Morphometry BIRN - Overview - Scientific Achievements.

Are spatial tasks useful for the early diagnosis of Alzheimer’s disease.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.

Medical Image SBIA.UPenn Christos Davatzikos Director, Section of Biomedical Image Analysis Professor, Radiology,

Wei Chen CCNI Journal Club Alzheimer’s disease (AD): imaging & cognition imaging & cognition.

Neuroimage Analysis Center An NCRR National Resource Center Time Series MRI Core Analysis, Modeling - toward Dynamic Surrogates.

NA-MIC National Alliance for Medical Image Computing Mental Illness and Neuroscience Discovery (MIND) Consortium Data Randy L. Gollub,

conflicts of interest to report.

Fresh Ideas on Architecture of Cognitive Processing and Alzheimer's Disease Pathogenesis: Possibilities for Translation into Clinical Practice Goran Šimić.

The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop an infrastructure that efficiently enables the undertaking of adaptive,

References [1] Coupé et al., An optimized blockwise nonlocal means denoising filter for 3-D magnetic resonance images. IEEE TMI, 27(4):425–441, 2008.

Structural MRI as a Biomarker of Disease Progression in AD Department of Diagnostic Radiology and MRI Research Lab Presented by Clifford Jack, M.D. at.

UCI Progress MBIRN AHM. Progress Tool Development –FIPS and HID: Modifications to store derived data, including morphometric measures from Freesurfer.

UMCG/RuG BCN - NIC Journal club 25 Apr. ’08 A method for functional network connectivity among spatially independent resting-state components in schizophrenia.

Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Sven Haller Haller, Nguyen, Rodriguez, Emch, Gold, Bartsch, Lovblad, Giannakopoulos.

Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of Short- term conversion to AD: Results from ADNI Xuejiao.

INFLUENCE OF FRACTIONAL ANISOTROPY THRESHOLD FOR TRACT BASED DIFFUSION TENSOR ANALYSIS OF UNCINATE FASCICLES IN ALZHEIMER DISEASE Toshiaki Taoka, Toshiaki.

SUMMARY: PharmaCOG WP5/E-ADNI European JPND Call: Acquisition Harmonization E-ADNI update and related activities WW-ADNI yearly meeting AAIC, Toronto,

DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)

Update of China-ADNI Kuncheng Li, MD. PhD.

EUROPEAN ADNI/PharmaCOG

EUROPEAN ADNI (PharmaCog, EPAD, AMYPAD, SRA-NED) Jorge Jovicich

Volume 3, Issue 4, Pages (November 2017)

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

MTL SUBREGIONAL MORPHOMETRY USING HIGH RESOLUTION MRI IN ADNI2

Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73

Update of China-ADNI Kuncheng Li, MD. PhD.

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Presenter: Dr. Patricio Chrem

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Volume 2, Issue 1, Pages (January 2016)

Imaging AD Progression Amyloid Imaging Agents.

Early Dementia Distinguishing AD From MCI

EUROPEAN ADNI (PharmaCog, EPAD, AMYPAD, SRA-NED) Jorge Jovicich

Assessing Disease Progression in MS Treatment

Presenter: Dr. Patricio Chrem

Update of China-ADNI Kuncheng Li, MD. PhD.

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Todd E. Golde, Lon S. Schneider, Edward H. Koo Neuron

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Schematic overview of the immuno‐infrared‐sensor, the assay read‐out, and BioFINDER and ESTHER study design Schematic overview of the immuno‐infrared‐sensor,

European Prevention Alzheimer’s Dementia

Figure 1 NMF in ADD patients and classification of prodromal Alzheimer’s disease participants. Grey matter ... Figure 1 NMF in ADD patients and classification.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis The rate.

Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;

Presentation transcript:

PharmaCog WP5 / E-ADNI

Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED

JournalTitleStatusAuthor Journal of Internal Medicine Clinical and biomarker profiling of prodromal Alzheimer’s disease in IMI Pharmacog’s WP5: a “European ADNI study” SubmittedGalluzzi et al. Human Brain MappingTest-Retest Reliability of the Default Mode Network in a Multicentric fMRI Elderly Study: Effects of Data-Driven Physiological Noise Correction Techniques SubmittedMarchitelli et al Human Brain MappingLongitudinal reproducibility of automatically segmented hippocampal subfields: a multi-site European 3T study on healthy elderly Published in Sept 2015 Marizzoni et al. NeuroImageLongitudinal reproducibility of default-mode network connectivity in healthy elderly participants: a multicentric resting-state fMRI study Published in July 2015 Jovicich et al. NeuroImageMultisite Longitudinal Reliability of Tract-Based Spatial Statistics in Diffusion Tensor Imaging of Healthy Elderly Subjects Published in Nov 2014 Jovicich et al. Drug Discovery Today: Therapeutic Strategies A new paradigm for testing AD drugs – neuroimaging biomarkers as surrogate outcomes homologous in animals and humans Published in Oct 2014 Marizzoni et al. NeuroImageBrain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations Published in Dec 2013 Jovicich et al. Journal of Alzheimer’s Disease Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stagePublished in Aug 2011 Drago et al. Peer-reviewed Publications

Baseline CSF Aβ, Aβ/t-tau and Aβ/p-tau distributions to classify PharmaCog MCI patients

Cognitive and hippocampal volume changes

Series of papers in preparation The IMI PharmaCog WP5/European ADNI study: status and progression of prodromal AD as revealed by a matrix of clinical, neuropsychological, and biological markers Peer-reviewed Publications Introduction Cross-sectional papers Longitudinal papers 22 papers divided into Special issue of peer-reviewed journal